Physiomics Share Price | |
---|---|
Price | 1.30 |
Bid | 1.20 |
Ask | 1.40 |
Change | 0.15 (13.04%) |
Volume | 1,153,587 |
Open | 1.15 |
High | 1.30 |
Low | 1.15 |
Prev. Close | 1.15 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 135.47m |
Market Capitalisation | £1.76m |
Market Size | 30,000 |
52 Week High | 3.15 |
52 Week High Date | 10-May-2023 |
52 Week Low | 0.925 |
52 Week Low Date | 09-Aug-2023 |
# Trades | 54 |
---|---|
Vol. Sold | 920 |
Sold Value | £N/A |
Vol. Bought | 1,152,667 |
Bought Value | £14.64k |
PE Ratio | -2.653061 |
Earnings | -0.49 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
19-Apr-24 | 16:27:01 | 1.39 | 125,144 | Buy* | 1.20 | 1.40 | 1,740 | O Ordinary |
19-Apr-24 | 16:17:20 | 1.39 | 73 | Buy* | 1.20 | 1.40 | 1.01 | O Ordinary |
19-Apr-24 | 15:48:14 | 1.395 | 6,380 | Buy* | 1.20 | 1.40 | 89.00 | O Ordinary |
19-Apr-24 | 14:12:44 | 1.3998 | 1,500 | Buy* | 1.20 | 1.40 | 21.00 | O Ordinary |
19-Apr-24 | 14:04:03 | 1.40 | 4,000 | Buy* | 1.20 | 1.40 | 56.00 | O Ordinary |
19-Apr-24 | 14:01:38 | 1.3998 | 14,287 | Buy* | 1.20 | 1.40 | 199.99 | O Ordinary |
19-Apr-24 | 13:59:11 | 1.3998 | 5,000 | Buy* | 1.20 | 1.40 | 69.99 | O Ordinary |
19-Apr-24 | 13:56:18 | 1.3998 | 21,500 | Buy* | 1.20 | 1.40 | 300.96 | O Ordinary |
19-Apr-24 | 13:47:11 | 1.3998 | 3,500 | Buy* | 1.20 | 1.40 | 48.99 | O Ordinary |
19-Apr-24 | 13:32:12 | 1.3998 | 5,000 | Buy* | 1.20 | 1.40 | 69.99 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
25-Jul-23 | 22-Jul-23 | Transfer To | James Simon Millen held the position of Executive Chairman at the time of this trade.James Simon Millen | 0.00 | 500,000 | 1,884,393 | |
18-Jul-23 | 14-Jul-23 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 500,000 | 1,102,723 | |
29-Jun-21 | 28-Jun-21 | Transfer To | Christophe Chassagnole held the position of COO at the time of this trade.Christophe Chassagnole | 0.00 | 85,715 | 602,723 | |
21-May-21 | 21-May-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 | |
22-Mar-21 | 29-Jan-21 | Transfer To | James Simon Millen held the position of CEO at the time of this trade.James Simon Millen | 0.00 | 242,287 | 1,384,393 |
Physiomics is a leading oncology drug development consultancy using proprietary state of the artVirtual Tumour™ technology and other tools to predict and better understand the effects of cancer treatments. We work with partners developing cancer drugs to help them save time and money during pre-clinical and clinical development.